Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Debt Repayment

Cash used to repay borrowings during the period.

Codexis, Inc.NASDAQ: CDXS

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow grows to $0

Q1 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $9.9M.

Context

  • Debt repayment amounted to 14.1% of revenue in FY2025, down 35.7 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.47M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$9.89M-66.5% YoY
LTMMar 2026
$9.9M+133.3% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-66.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
9.89M USD
Year-over-year change
-66.5%

Debt Repayment vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +133.3% is the 2nd highest of 5, against a peer median of +89.8%.
  • Debt repayment amounts to 12.7% of revenue for CDXS, versus a peer median of 14.2%.
CDXS Competitors
Debt Repayment for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$16.97M USD+94.0%—535.6%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$15M USD+160.3%—507.1%
CDXSCodexis, Inc.LTM Mar 2026$9.9M USD+133.3%—12.7%
IPHAInnate Pharma S.A.FY2025€8.56M EUR-4.2%+61.7%307.1%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$555K USD+85.6%-29.1%28.5%
OABIOmniAb, Inc.LTM Mar 2026$0 USD——0.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
IVVDInvivyd, Inc.LTM Mar 2026$0 USD——0.0%
TARAProtara Therapeutics, Inc.LTM Mar 2026$0 USD———
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CDXS) —+89.8%+16.3%14.2%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Depreciation & Amortization5.95M10.25M9.92M4.95M5.25M
Deferred Income Tax(2.89M)0000
Stock-Based Compensation11.59M14.53M9.97M13.09M9.62M
Change in Working Capital(7.62M)21.57M(18.22M)(12.02M)6.42M
Accounts Receivables(15.57M)(3.23M)20.25M1.25M8.51M
Inventory(196K)(869K)(656K)886K(19K)
Accounts Payables268K207K2.29M(2.57M)(1.29M)
Other Working Capital7.88M25.46M(40.1M)(11.59M)(784K)
Other Non-Cash Items(19K)(1.48M)21.93M9.85M3.31M
Operating Cash Flow(14.27M)11.28M(52.64M)(49.41M)(19.38M)
Capital Expenditures(13.83M)(8.31M)(4.42M)(4.31M)(4.47M)
Acquisitions (Net)36K29K751K87K5K
Purchases of Investments(7.63M)(5.3M)(1.19M)(90.24M)(57.16M)
Sales of Investments(36K)(29K)440K37.47M85.13M
Other Investing Activities36K29K(440K)00
Investing Cash Flow(21.42M)(13.58M)(4.86M)(56.98M)23.5M
Debt Repayment00029.52M9.89M
Common Stock Issued4.97M913K8.65M31.32M18.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.21M)(1.49M)(485K)(318K)0
Financing Cash Flow3.77M(575K)8.17M60.52M27.93M
Effect of Forex Changes00000
Net Change in Cash(31.92M)(2.87M)(49.33M)(45.87M)32.05M
Free Cash Flow(28.1M)2.98M(57.06M)(53.72M)(23.85M)

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.